ledipasvir + sofosbuvir + ribavirin

This drug is a combination therapy consisting of **ledipasvir**, **sofosbuvir**, and **ribavirin**—used primarily for the treatment of chronic hepatitis C virus (HCV), most commonly genotype 1, including in patients with advanced liver disease or following a liver transplant. Ledipasvir is an inhibitor of the hepatitis C virus (HCV) NS5A protein, which interferes with viral replication and assembly. Sofosbuvir is a nucleotide analog inhibitor of HCV NS5B polymerase, acting as an RNA chain terminator during viral RNA replication. Ribavirin is a nucleoside analog with broad-spectrum antiviral activity, traditionally used in HCV treatment to improve probability of sustained virologic response when combined with other antivirals. Combination therapy with all three agents is reserved for specific populations, such as patients with decompensated cirrhosis or post-transplant infection, and has demonstrated high cure rates (SVR12) in clinical studies[1][2][3][4][6][7].

Brand names

Harvoni

Other names

sofosbuvir, ribavirin, and ledipasvir triple therapy